The FDA sent a letter to Allergan expressing concerns that the eyelash growth drug Latisse is being incorrectly promoted as a cosmetic product. The active ingredient, bimatoprost, clearly affects the structure and function of the body and is therefore not a cosmetic, according to the FDA definition of a cosmetic product. Interestingly, Allergan had been involved in a lawsuit against Jan Marini Skin Research to force them to discontinue selling a cosmetic product that utilizes this ingredient. Allergan has also received the more severe FDA warning for inappropriate promotion of their acne medication “Aczone”. The FDA claims that the study cited by Allergan is a “complete misrepresentation” of the results. Allergan, which has a track record of innovative promotional ploys, has drawn the attention of the FDA and is apparently under heightened scrutiny due to repeated problems in this area. Allergan claims they are working closely with the FDA to address all of their concerns.